The marketing of oral medications for weight loss is the most competitive battleground in the pharmaceutical industry. Looking at it now, Eli Lilly is at a disadvantage in the fight against rival Novo Nordisk. According to the latest week's data, since Foundayo, its weight loss oral drug, went on sale in April, Eli Lilly has accounted for about 11% of the new oral drug prescriptions. Novo Nordisk's Weishumei oral medication launched in January accounts for the remaining share. This is a remarkable change for the nearly $80 billion anti-obesity drug market — a market that is currently one of the hottest segments of the pharmaceutical industry. Eli Lilly dominates injectable sales. Analysts originally thought the company's oral medications would also win big. The doctor pointed out that one of the challenges Eli Lilly faced was clinical research data: patients taking Novo Nordisk's oral medication lost an average of 16.6% of their body weight after more than a year of medication, while those taking Foundayo lost an average weight of only 12.4%. Analysts said that another reason for slowing down the pace of rewards is that it took the company a long time to obtain reimbursement from the health insurance plan.

The marketing of oral medications for weight loss is the most competitive battleground in the pharmaceutical industry. Looking at it now, Eli Lilly is at a disadvantage in the fight against rival Novo Nordisk. According to the latest week's data, since Foundayo, its weight loss oral drug, went on sale in April, Eli Lilly has accounted for about 11% of the new oral drug prescriptions. Novo Nordisk's Weishumei oral medication launched in January accounts for the remaining share. This is a remarkable change for the nearly $80 billion anti-obesity drug market — a market that is currently one of the hottest segments of the pharmaceutical industry. Eli Lilly dominates injectable sales. Analysts originally thought the company's oral medications would also win big. The doctor pointed out that one of the challenges Eli Lilly faced was clinical research data: patients taking Novo Nordisk's oral medication lost an average of 16.6% of their body weight after more than a year of medication, while those taking Foundayo lost an average weight of only 12.4%. Analysts said that another reason for slowing down the pace of rewards is that it took the company a long time to obtain reimbursement from the health insurance plan.